Intravesically instilled gemcitabine-induced lung injury in a patient with invasive urothelial carcinoma: A case report

作     者：Xiao-Ming Zhou Cen Wu Xiu Gu 

作者机构：Department of Respiratory and Critical Care MedicineShengjing Hospital of China Medical UniversityShenyang 110004Liaoning ProvinceChina Department of Respiratory and Critical Care MedicineFourth Hospital of China Medical UniversityShenyang 110004Liaoning ProvinceChina Department of Pulmonary and Critical Care MedicineShengjing Hospital of China Medical UniversityShenyang 110004Liaoning ProvinceChina 

出 版 物：《World Journal of Clinical Cases》 (世界临床病例杂志)

年 卷 期：2020年第8卷第19期

页      面：4652-4659页

核心收录：

学科分类：1002[医学-临床医学] 100214[医学-肿瘤学] 10[医学] 

主　　题：Gemcitabine Interstitial lung disease Lung injury Organizing pneumonitis Urothelial carcinoma Case report Chemotherapy toxicity 

摘      要：BACKGROUND Gemcitabine is a chemotherapy agent with relatively low toxicities,as a valid option for elderly patients with underlying ***-induced pulmonary toxicities are rare and various,ranging from self-limited episodes of bronchospasm to fatal,progressive,severe,interstitial pneumonitis and respiratory *** gemcitabine instillations are commonly used to reduce recurrence or progression for non-muscle-invasive bladder cancer or urothelial *** severe toxicities have been reported for the intravesical instillation is assumed to be completely separated from the systemic *** SUMMARY A 67-year-old patient received 30 cycles of intravesical gemcitabine instillation after transurethral resection and developed a 1-wk fever,cough,hemoptysis,and *** a thorough checkup,bilateral consolidation and infiltration of the lungs were documented and a percutaneous lung biopsy confirmed organizing pneumonia after treatment with broad-spectrum empirical antibiotics *** corticosteroids were administered,and pulmonary toxicity gradually *** Gemcitabine-induced pulmonary toxicities present with various *** spite of the rare pulmonary involvement by the intravesical gemcitabine instillation,health care professionals who administer gemcitabine chemotherapy in this way should monitor for gemcitabine-induced pulmonary toxicities,particularly in patients with high-risk factors.